Background The incidence of anemia increases with the stage of chronic kidney disease
(CKD). Erythropoietin (EPO) deficiency is the common cause of anemia in CKD …

Abstract Background: Erythropoiesis-stimulating agents (ESAs) are used to treat anemia in
CKD. Erythropoietin resistance index (ERI) is a useful tool used to evaluate the response to …

Anemia is common in chronic kidney disease (CKD). Erythropoietin is the standard
treatment for anemia of CKD. We evaluated the frequency and etiologies of erythropoietin …

Background: Anemia is a common complication associated with chronic kidney disease
(CKD), and optimal treatment requires appropriate diagnosis, recombinant human …

Background: Erythropoiesis-stimulating agent (ESA) resistance remains incompletely
understood among hemodialysis (HD) patients. Method: A retrospective, multicenter study …

Anemia is an inevitable complication of hemodialysis, and the primary cause is
erythropoietin deficiency. After diagnosis, treatment begins with an erythropoiesis …

Routine administration of erythropoietin (EPO)-stimulating agents (ESAs) for the control of
anemia has improved the quality of life of subjects with chronic kidney disease (CKD) …

Background: Anemia resistant to erythropoietin stimulating agents (ESAs) is a risk factor for
all-cause mortality. Determining the etiologies of hyporesponsiveness may help overcome …

Previous studies often report lower responses to erythropoietin (EPO) therapy in pediatric
patients on chronic dialysis than those of adults. Because of the greater capacity for …

Background: A definite anemia [hemoglobin (HB) 10-12 g/dl] or the need for significantly
higher Erythropoietin (EPO) dosages of epoetin alfa are symptoms of EPO resistance …